CoChat
Sign Up
Cited by 9Multiple Myeloma Research and TreatmentsCancer survivorship and careBone health and treatments

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Evidence-Based Guidelines for Preventing and Managing Side Effects of Multiple Myeloma

Bertolotti, Page, Pierre, Amy, Rome, Sandra, Faiman, Beth·2017·Seminars in Oncology Nursing
DOI 10.1016/j.soncn.2017.05.008
Open this paper in CoChat — free account

Abstract

Objective To review disease-related symptoms and side effects of treatment in patients with multiple myeloma (MM). Data sources Peer-reviewed articles, research studies, and clinical guidelines. Conclusion New therapies provide patients with extended survival, but in many cases this benefit is counterbalanced by an increased incidence of side effects. Preservation of organ function, while managing side effects, is essential for the care of patients with MM. Implications for nursing practice Disease- and treatment-related adverse events are prevalent in patients with MM. Patient, family, and health care professional education is essential to monitor and manage these side effects.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.soncn.2017.05.008

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 82

  1. Steinbach, 2017, Strategies for selecting the optimal treatment in newly-diagnosed multiple myeloma patients, Semin Oncol Nurs, 33, 10.1016/j.soncn.2017.05.003 · DOI
  2. Noonan, 2017, Immunomodulatory drugs and protease inhibitors in the treatment of multiple myeloma, Semin Oncol Nurs, 33, 10.1016/j.soncn.2017.05.005 · DOI
  3. Catamero, 2017, Immunotherapy in multiple myeloma, Semin Oncol Nurs, 33
  4. Terpos, 2014, Management of bone disease in multiple myeloma, Expert Rev Hematol, 7, 113, 10.1586/17474086.2013.874943 · DOI
  5. Roodman, 2004, Mechanisms of bone metastasis, N Engl J Med, 350, 1655, 10.1056/NEJMra030831 · DOI
  6. Rajkumar, 2014, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, 15, e538, 10.1016/S1470-2045(14)70442-5 · DOI · Paper page
  7. Dimopoulos, 2015, Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement, J Clin Oncol, 33, 657, 10.1200/JCO.2014.57.9961 · DOI
  8. Brigle, 2017, Pathobiology and diagnosis of multiple myeloma, Semin Oncol Nurs, 10.1016/j.soncn.2017.05.012 · DOI
  9. Terpos, 2003, Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single center experience in 127 patients, Bone Marrow Transplant, 31, 163, 10.1038/sj.bmt.1703818 · DOI
  10. Terpos, 2013, International Myeloma Working Group recommendations for the treatment of multiple myeloma–related bone disease, J Clin Oncol, 31, 2347, 10.1200/JCO.2012.47.7901 · DOI
  11. Terpos, 2015, European Myeloma Network guidelines for the management of multiple myeloma-related complications, Haematologica, 100, 1254, 10.3324/haematol.2014.117176 · DOI
  12. Rosen, 2003, Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double blind, multicenter, comparative trial, Cancer, 98, 1735, 10.1002/cncr.11701 · DOI
  13. Morgan, 2011, Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial, Lancet Oncol, 12, 743, 10.1016/S1470-2045(11)70157-7 · DOI
  14. Von Moos, 2010, Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with advanced cancer (excluding breast and prostate) or multiple myeloma (MM): results from a randomized phase III clinical trial, ASCO Meet Abstr, 28, 9043
  15. Raje, 2013, Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study, ASCO Meet Abstr, 31, 8589
  16. Rome, 2011, Mobility and safety in the multiple myeloma survivor: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board, Clin J Oncol Nurs, 15, 41, 10.1188/11.S1.CJON.41-52 · DOI
  17. Miceli, 2011, Maintaining bone health in patients with multiple myeloma, Clin J Oncol Nurs, 15, 9, 10.1188/11.S1.CJON.9-23 · DOI
  18. Coleman, 2003, Facilitating exercise adherence for patients with multiple myeloma, Clin J Oncol Nurs, 7, 529, 10.1188/03.CJON.529-534 · DOI
  19. Finkel, 2016, Paraprotein-related kidney disease: evaluation and treatment of myeloma cast nephropathy, Clin J Am Soc Nephrol, 11, 2256, 10.2215/CJN.01640216 · DOI
  20. Dimopoulos, 2008, Pathogenesis and treatment of renal failure in multiple myeloma, Leukemia, 22, 1485, 10.1038/leu.2008.131 · DOI
  21. Dimopoulos, 2016, International Myeloma Working Group Recommendations for the diagnosis and management of myeloma-related renal impairment, J Clin Oncol, 34, 1544, 10.1200/JCO.2015.65.0044 · DOI
  22. Faiman, 2011, Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board, Clin J Oncol Nurs, 15, 66, 10.1188/11.CJON.S1.66-76 · DOI
  23. Inker, 2014, KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD, Am J Kidney Dis, 63, 713, 10.1053/j.ajkd.2014.01.416 · DOI
  24. Kurtin, 2012, Myeloid toxicity of cancer treatment, J Adv Pract Oncol, 3, 209
  25. Valkovic, 2015, Infections in hospitalised patients with multiple myeloma: main characteristics and risk factors, Turk J Haematol, 32, 234, 10.4274/tjh.2013.0173 · DOI
  26. Huang, 2017, Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma, BMC Infect Dis, 17, 33, 10.1186/s12879-016-2155-1 · DOI
  27. Crea, 2009, Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization, Crit Rev Oncol Hematol, 72, 21, 10.1016/j.critrevonc.2008.10.014 · DOI
  28. Miceli, 2008, Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board, Clin J Oncol Nurs, 12, 13, 10.1188/08.CJON.S1.13-19 · DOI
  29. Moreau, 2016, Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma, N Engl J Med, 374, 1621, 10.1056/NEJMoa1516282 · DOI · Paper page
  30. Palumbo, 2012, How to manage neutropenia in multiple myeloma, Clin Lymphoma Myeloma Leuk, 12, 5, 10.1016/j.clml.2011.11.001 · DOI
  31. Gay, 2010, Management of disease- and treatment-related complications in patients with multiple myeloma, Med Oncol, 27, S43, 10.1007/s12032-010-9542-z · DOI
  32. Palumbo, 2014, International Myeloma Working Group Consensus Statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation, J Clin Oncol, 32, 587, 10.1200/JCO.2013.48.7934 · DOI
  33. Faller, 2016, Immune thrombocytopenia purpura associated with multiple myeloma, Ann Hematol, 95, 1371, 10.1007/s00277-016-2694-y · DOI
  34. Gonsalves, 2016, Limiting early mortality: do's and don'ts in the management of patients with newly diagnosed multiple myeloma, Am J Hematol, 91, 101, 10.1002/ajh.24129 · DOI
  35. Smith, 2015, Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 33, 3199, 10.1200/JCO.2015.62.3488 · DOI
  36. Rizzo, 2010, American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer, Blood, 116, 4045, 10.1182/blood-2010-08-300541 · DOI
  37. Slichter, 2010, Dose of prophylactic platelet transfusions and prevention of hemorrhage, N Engl J Med, 362, 600, 10.1056/NEJMoa0904084 · DOI
  38. Leebeek, 2016, Update of thrombosis in multiple myeloma, Thromb Res, 140, S76, 10.1016/S0049-3848(16)30103-7 · DOI
  39. Baz, 2005, The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma, Mayo Clin Proc, 80, 1568, 10.4065/80.12.1568 · DOI
  40. Palumbo, 2008, Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma, Leukemia, 22, 414, 10.1038/sj.leu.2405062 · DOI
  41. Rome, 2008, Thromboembolic events associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board, Clin J Oncol Nurs, 12, 21, 10.1188/08.CJON.S1.21-27 · DOI
  42. Elice, 2006, Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism, Br J Haematol, 134, 399, 10.1111/j.1365-2141.2006.06208.x · DOI
  43. Niesvizky, 2010, Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia, J Natl Compr Canc Netw, 8, S13, 10.6004/jnccn.2010.0112 · DOI
  44. Li, 2016, Cardiovascular complications of novel multiple myeloma treatments, Circulation, 133, 908, 10.1161/CIRCULATIONAHA.115.018351 · DOI
  45. Auwerda, 2007, Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma, Haematologica, 92, 279, 10.3324/haematol.10454 · DOI
  46. Van Marion, 2008, Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens, Leuk Res, 32, 1078, 10.1016/j.leukres.2007.12.002 · DOI
  47. Minnema, 2003, Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment, J Thromb Haemost, 1, 445, 10.1046/j.1538-7836.2003.00083.x · DOI
  48. Rickles, 2003, TIssue factor, thrombin, and cancer, Chest, 124, 58S, 10.1378/chest.124.3_suppl.58S · DOI
  49. Auwerda, 2011, Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma, Thromb Haemost, 105, 14, 10.1160/TH10-03-0187 · DOI
  50. Srkalovic, 2004, Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease, Cancer, 101, 558, 10.1002/cncr.20405 · DOI
  51. Baz, 2014, Pomalidomide, cyclophosphamide, and dexamethasone is superior to pomalidomide and dexamethasone in relapsed and refractory myeloma: results of a multicenter randomized phase II study, Blood, 124, 303, 10.1182/blood.V124.21.303.303 · DOI
  52. Rajkumar, 2010, Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial, Lancet Oncol, 11, 29, 10.1016/S1470-2045(09)70284-0 · DOI · Paper page
  53. Anaissie, 2012, Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis, Cancer, 118, 549, 10.1002/cncr.26302 · DOI
  54. Lee, 2010, Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants, Hematology Am Soc Hematol Educ Program, 2010, 144, 10.1182/asheducation-2010.1.144 · DOI
  55. Lyman, 2015, Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014, J Clin Oncol, 33, 654, 10.1200/JCO.2014.59.7351 · DOI
  56. Kristinsson, 2010, Thrombosis in multiple myeloma, Hematology Am Soc Hematol Educ Program, 2010, 437, 10.1182/asheducation-2010.1.437 · DOI
  57. Bagratuni, 2013, Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens, Am J Hematol, 88, 765, 10.1002/ajh.23504 · DOI
  58. Zangari, 2011, Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens, Clin Lymphoma Myeloma Leuk, 11, 228, 10.1016/j.clml.2011.03.006 · DOI
  59. Lee, 2015, Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients, Thromb Res, 136, 974, 10.1016/j.thromres.2015.09.021 · DOI
  60. Richardson, 2012, Management of treatment-emergent peripheral neuropathy in multiple myeloma, Leukemia, 26, 595, 10.1038/leu.2011.346 · DOI
  61. Broyl, 2012, General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma, Semin Hematol, 49, 249, 10.1053/j.seminhematol.2012.04.001 · DOI
  62. Mohty, 2010, Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations, Haematologica, 95, 311, 10.3324/haematol.2009.012674 · DOI
  63. Tariman, 2008, Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board, Clin J Oncol Nurs, 12, 29, 10.1188/08.CJON.S1.29-35 · DOI
  64. Stephens, 2014, The work of living with a rare cancer: multiple myeloma, J Adv Nurs, 70, 2800, 10.1111/jan.12430 · DOI
  65. Poncelet, 1998, An algorithm for the evaluation of peripheral neuropathy, Am Fam Physician, 755
  66. Klimberg, 2005, Is glutamine effective in enhancing host immune response to tumors?, J Nutr, 135, 2920S, 10.1093/jn/135.12.2920S · DOI
  67. Hansen, 2006, Glutamine supplementation to reduce oral mucositis in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation: a feasibility study, Biol Blood Marrow Transplant, 12, 144, 10.1016/j.bbmt.2005.11.441 · DOI
  68. Wang, 2007, Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients, Oncologist, 12, 312, 10.1634/theoncologist.12-3-312 · DOI
  69. Amara, 2008, Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy, Ann Pharmacother, 42, 1481, 10.1345/aph.1L179 · DOI
  70. Smith, 2013, Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial, JAMA, 309, 1359, 10.1001/jama.2013.2813 · DOI
  71. Majithia, 2016, New practical approaches to chemotherapy-induced neuropathic pain: prevention, assessment, and treatment, Oncology, 30
  72. Dobson, 2014, Benefits of exercise intervention in reducing neuropathic pain, Front Cell Neurosci, 8, 102, 10.3389/fncel.2014.00102 · DOI
  73. Hershman, 2014, Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, 32, 1941, 10.1200/JCO.2013.54.0914 · DOI
  74. Faiman, 2016, Diarrhea in multiple myeloma: a review of the literature, Clin J Oncol Nurs, 20, E100, 10.1188/16.CJON.E100-E105 · DOI
  75. Ritts, 2016, Cardiac consideration for modern multiple myeloma therapies, Am Coll Cardiol
  76. Shakir, 2009, Chemotherapy induced cardiomyopathy: pathogenesis monitoring and management, J Clin Med Res, 1, 8
  77. Ewer, 2015, Cardiotoxicity of anticancer treatments: what the cardiologist needs to know, Nat Rev Cardiol, 7, 564, 10.1038/nrcardio.2010.121 · DOI
  78. Bovelli, 2010, Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines, Ann Oncol, 21, v277, 10.1093/annonc/mdq200 · DOI
  79. Florescu, 2015, Chemotherapy-induced cardiotoxicity, J Clin Med, 8, 59
  80. Brana, 2010, Cardiotoxicity, Ann Oncol, 21, vii173, 10.1093/annonc/mdq295 · DOI
  81. Ritts, 2017, Current concepts of cardiac amyloidosis: diagnosis, clinical management, and the need for collaboration, Heart Fail Clin, 13, 409, 10.1016/j.hfc.2016.12.003 · DOI
  82. Okwusoa, 2015, Burgeoning cardio-oncology programs, challenges and opportunities for early career cardiologists/faculty directors, J Am Coll Cardiol, 66, 1193, 10.1016/j.jacc.2015.07.033 · DOI

Cited by

Sorted by citations

See all 9

Metadata

Authors
Bertolotti, P., Pierre, A., Rome, S., & Faiman, B.
Corresponding author
Bertolotti, Page
ORCID
Venue
Seminars in Oncology Nursing
Publisher
Elsevier BV
Published
2017-08
Volume
33
Issue
3
Pages
332-347
ISSN
0749-2081 (ISSN-L)
DOI
10.1016/j.soncn.2017.05.008
OpenAlex
W2739288118
Cited by
9
References
3
Citations by year
2025: 2 · 2024: 2 · 2022: 3 · 2021: 1 · 2017: 1
FWCI
0.04
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Seminars in Oncology Nursing (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
multiple myeloma, treatment side effects, adverse events, symptom management, organ function preservation, nursing care, patient education, family education, health professions education, evidence-based recommendations
MeSH terms
Antineoplastic Agents, Humans, Multiple Myeloma, Survival Analysis, Practice Guidelines as Topic, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evidence-Based Guidelines for Preventing and Managing Side Effects of Multiple Myeloma. https://app.cochat.ai/papers/10.1016/j.soncn.2017.05.008
The paper
Bertolotti, P., Pierre, A., Rome, S., & Faiman, B. (2017). Evidence-Based Guidelines for Preventing and Managing Side Effects of Multiple Myeloma. Seminars in Oncology Nursing. https://doi.org/10.1016/j.soncn.2017.05.008